This study investigates the extrusion-spheronization performance of some mixtures of co-processed microcrystalline cellulose and Eudragit® E (as excipients) and sorbitol (as soluble filler-disintegrant). Attention is focused on the dissolution rate of low water solubility drugs (hydrochlorothiazide is used as a model drug) from pellets prepared with these mixtures. All pellet formulations studied presented adequate morphological, flow and mechanical properties. The pellets prepared with co-processed MCC-Eudragit® E and sorbitol show a drug dissolution rate dependent on the content of Eudragit® E in the co-processed excipient and on the proportion of sorbitol incorporated. Furthermore, the pellets made with co-processed MCC-Eudragit® E incorporating the higher proportion of sorbitol (50%) show a very high dissolution rate of hydrochlorothiazide (HCT) and undergo rapid disintegration in the dissolution medium.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejpb.2011.07.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulatory Considerations for Stability Studies of Co-Processed Active Pharmaceutical Ingredient.
AAPS J
December 2024
Chemical Process R&D, Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA, 01752, USA.
A co-processed active pharmaceutical ingredient (CP API) is the combination of an active pharmaceutical ingredient (API) with non-active component(s). This technology has been demonstrated to offer numerous benefits, including but not limited to improved API properties and stability. The infrastructure requirements are such that the manufacture of a CP API is typically best suited for an API facility.
View Article and Find Full Text PDFKollidon® SR: Formulation techniques and drug delivery applications.
Int J Pharm
January 2025
Department of Pharmaceutical Sciences and Pharmaceutics, Faculty of Pharmacy, Applied Science Private University, Amman 11931, Jordan.
Kollidon® SR is one of the recent versatile coprocessed excipients in the formulation of modified-release dosage forms. It is prepared by co-spray drying aqueous dispersions of polyvinylacetate and polyvinylpyrrolidone. This article gives a critical review of the physicochemical attributes and technological properties of Kollidon® SR.
View Article and Find Full Text PDFEvaluation of the Potential of Novel Co-Processed Excipients to Enable Direct Compression and Modified Release of Ibuprofen.
Pharmaceutics
November 2024
Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
: Improving the production rates of modern tablet presses places ever greater demands on the performance of excipients. Although co-processing has emerged as a promising solution, there is still a lack of directly compressible excipients for modified-release formulations. The aim of the present study was to address this issue by investigating the potential of novel co-processed excipients for the manufacture of modified-release tablets containing ibuprofen.
View Article and Find Full Text PDFSilicified microcrystalline cellulose from renewable banana pseudostem: Physicochemical and functional analysis.
Int J Biol Macromol
December 2024
Department of Pharmaceutical Science, Assam University, Silchar, Assam 788011, India. Electronic address:
Microcrystalline cellulose (MCC) has been isolated from numerous sources through acid hydrolysis of mercerized cellulose. Due to the fibrous shape, its poor flow ability and lower compactibility, MCC is often co-processed with other excipients to improve its functional properties. Musa MCC was isolated from the pseudostem of Musa balbisiana and silicified with 2 % silicon dioxide (SMCC) through homogenization followed by filtration and oven drying.
View Article and Find Full Text PDFComparison of different processed products of for the treatment of mice asthenozoospermia.
Transl Androl Urol
October 2024
Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi, China.
Article Synopsis
- GZP, a co-processed mixture with salt and wine, effectively treats asthenozoospermia (reduced sperm motility) in mice by enhancing sexual function and testicular health.
- The study involved establishing a mouse model for the condition and testing six products, revealing GZP significantly improves sperm count, survival, and reduces deformities.
- GZP appears to work by inhibiting excessive mitophagy and maintaining mitochondrial integrity, reducing harmful reactive oxygen species (ROS), and blocking certain protein expressions related to cell death.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!